1330 Orange Ave., Ste 302
Coronado, CA 92118
Read financial tips and market updates in our weekly newsletter
Copyright © 2002 – 2023 Orion Capital Management LLC • Coronado, CA
Disclosure: Orion Capital Management LLC (“Orion”) is an investment advisor registered with the U.S. Securities and Exchange Commission (SEC). The firm offers advisory services in the State of California and in other jurisdictions where registered or exempted. Registration does not imply a certain level of skill or training. The information on Orion’s website or in its distributed commentary shall not be directly or indirectly interpreted as a solicitation of investment advisory services to persons or entities of another jurisdiction unless otherwise permitted by statute. Orion’s individualized responses to consumers in a particular state in the rendering of personalized investment advice for compensation shall not be made without the firm first complying with jurisdiction requirements or pursuant to an applicable state exemption.
The information on Orion’s website or in its distributed commentary is not investment, tax, accounting or legal advice. Orion is not a tax advisor. For tax advice individuals should consult their CPA. This information is also not an offer or a solicitation of an offer to buy or sell any security, or to be construed as an endorsement of any company, security, fund, or other securities or non-securities offering. This information should not be relied upon in the making of investment decisions. All content on this site is for informational purposes only, and nothing herein should be construed as an investment recommendation. Opinions expressed herein are solely those of Orion, unless otherwise specifically cited. Material presented is believed to be from reliable sources, but no representations are made by our firm as to other parties’ informational accuracy or completeness. All information or ideas described on Orion’s website or in its distributed commentary should be discussed in detail with an investor’s personal financial advisors and legal counsel prior to implementation.
Past performance is no indication of future results. Investment in securities involves significant risk and has the potential for partial or complete loss of funds invested.
The information on Orion’s website or in its distributed commentary is provided “AS IS” and without warranties of any kind, either express or implied. To the fullest extent permissible pursuant to applicable laws, Orion Capital Management LLC disclaims all warranties, express or implied, including, but not limited to, implied warranties of merchantability, non-infringement, and suitability for a particular purpose.
Testimonials or reviews on Orion’s website are from current clients. Orion does not compensate for reviews or testimonials and has no material conflicts with clients offering reviews.
Orion does not warrant that the information on Orion’s website or in its distributed commentary will be free from error. Your use of this information is at your sole risk. Under no circumstances shall Orion be liable for any direct, indirect, special or consequential damages that result from the use of, or the inability to use, the information provided on this site, even if Orion or an Orion authorized representative has been advised of the possibility of such damages. Information contained on this site should not be considered a solicitation to buy or an offer to sell any security, or a recommendation to buy or sell any security in any jurisdiction where such offer, solicitation, or recommendation would be unlawful or unauthorized.
Schedule a quick introductory call with you and see if we would be a good fit for you.
Vaccine Progress Buoys Investors
Investors Keeping Faith
As confirmed virus cases continue to grow across the U.S., predominately on the West Coast and in the Sunbelt, investors seem to be maintaining their confidence that a solution to the Covid-19 challenge is within sight. So far, the Federal Reserve and Congress have acted forcefully to shore up the economy during this crisis and progress is being made along many avenues on the medical front as well.
Second Quarter Earnings Down Sharply. . . but not Horrific
As we get deeper into the second quarter earnings season, companies are reporting profit numbers that are slightly better than the grisly numbers analysts had penciled in. With about one-quarter of S&P 500 companies having reported, about 80% are doing better in terms of expected earnings-per-share (EPS) and around 70% have reported higher-than-expected revenues. Companies are, of course, mostly stepping over lowered bars that they themselves dropped as the virus spread. In aggregate, earnings are likely to be around 40% below the year-ago levels. In the big picture, though, earnings have been palatable to investors so far.
Market Forecast: Hazy with a Chance of Storms
Most managements are reluctant to forecast the trajectories of their businesses for the second half of the year, given the economic disruptions. Investors, however, have mostly taken the cloudy views in stride. On July 22nd, the S&P 500 Index closed at 3276.02, its highest level since the lockdowns began and slightly above where it began the year. (It has given up a bit of ground since.) Considering what has happened to the U.S. and global economies in recent months and the amount of uncertainty we still face, most strategists agree that equities have notched an admirable performance. We believe investor optimism is largely rooted in the rapid headway that the many companies and entities working on Covid-19 vaccines and treatments are reporting.
Multiple Shots on Goal for Vaccine Success
At least 165 separate efforts are underway worldwide to develop a Covid-19 vaccine. Of these, 27 are in human trials. Four are in Phase III, the last phase before potential approval for use. Recent trial results from three specific programs, in particular, seem to have given investors comfort that a scientific solution to this problem is at hand. Boston-based Moderna is conducting a 30,000 patient Phase III trial that begins nationwide on Monday. Swedish-British drugmaker AstraZeneca and Oxford University are also teaming up on what looks to be a promising vaccine and have committed to deliver at least one billion doses. U.S.-based Pfizer and Germany’s BioNTech are developing a vaccine for which the U.S. government has already ordered 100 million doses at a cost of nearly $2 billion. It is still too early to project precisely when a vaccine will be ready, but the data from the trials thus far indicate Covid-19 is not an uncrackable nut.
As always, I welcome your comments and feedback. Feel free to call or email us to discuss your portfolio or the markets.
Images via Canva.com
Join Our list!
Join our email newsletter list to receive more market updates and financial articles like this one.
Markets Not Toeing the Fed’s Line
In the opening weeks of 2023, equity markets here in the U.S. and around the world have performed well, signaling
Can the Fed Stick the Landing?
2023 Investment Outlook In 2022, inflation spiked around the world because of supply chain constraints, massive pandemic-era fiscal stimulus and
2022 Year-End Financial Checklist
2022 has delivered way more than its fair share of uncertainty and stress for investors. Taking stock of your complete
Peter Thoms, CFA, MBA